BioCryst Pharmaceuticals, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2010 | $43.9M | $109.4M | $13.6M |
| FY2011 | $67.4M | $82.2M | $16.4M |
| FY2012 | $57.9M | $57.4M | $20.9M |
| FY2013 | $50.0M | $48.9M | $21.2M |
| FY2014 | $61.2M | $136.9M | $54.5M |
| FY2015 | $74.6M | $122.4M | $28.9M |
| FY2016 | $88.3M | $89.8M | $22.1M |
| FY2017 | $94.5M | $178.3M | $50.3M |
| FY2018 | $97.6M | $146.8M | $26.7M |
| FY2019 | $137.0M | $175.3M | $114.2M |
| FY2020 | $354.0M | $334.7M | $272.1M |
| FY2021 | $695.1M | $588.2M | $504.4M |
| FY2022 | $844.6M | $550.0M | $304.8M |
| FY2023 | $972.5M | $517.0M | $110.6M |
| FY2024 | $966.4M | $490.4M | $104.7M |
| FY2025 | $633.3M | $514.2M | $89.7M |